With reference to the notice of Board Meeting dated January 28, 2022, Advanced Enzyme Technologies has informed that the Board of Directors at its Meeting held on February 05, 2022 (commenced at 10:55 am and concluded at 11:30 am) has, approved the following: Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2021 and Allotment of 9,200 Equity Shares of face value of Rs 2 at an exercise price of Rs 60 per share pursuant to exercise of options under the Employees Stock Option Scheme, 2015 (amended). In view of the above, the following documents are enclosed: Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended December 31, 2021 along with the Limited Review report issued by MSKA & Associates, Statutory Auditors of the Company as an Annexure. The aforesaid un-audited Financial Results along with Limited Review Report are also being uploaded on the website of the Company, www.advancedenzymes.com.
The above information is a part of company’s filings submitted to BSE.
